Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/17/2025

ARIA Risk Management in Patients Treated with Leqembi

Introduction to ARIA and Its Types

  • ARIA (Amyloid-Related Imaging Abnormalities) consists of two main types: ARIA-E (Brain edema or sulcal effusions) and ARIA-H (Hemosiderin deposits, including microhemorrhages and superficial siderosis) [1]

Baseline Assessment and Monitoring

  • Baseline MRI is essential to assess for pre-existing conditions that might increase the risk of ARIA in patients treated with Leqembi [1]
  • The American Academy of Neurology recommends that patients with homozygous APOE ε4 should be informed of their substantially higher risk of ARIA, and more vigilant MRI monitoring may be warranted, especially during the first 3-6 months of treatment [1]

Risk Factors for ARIA

  • Patients with pre-existing microhemorrhages, especially those with ≥2 microhemorrhages or superficial siderosis at baseline, have an increased risk of ARIA [1]
  • Anticoagulant use significantly increases the risk of intracerebral hemorrhage in patients treated with Leqembi [1]
  • Higher dosages of anti-amyloid antibodies increase the risk of ARIA [1]

Clinical Assessment and Symptoms

  • Clinicians should watch for symptoms such as headache, confusion, visual disturbances, dizziness, gait difficulties, nausea, and in rare cases, seizures or status epilepticus in patients treated with Leqembi [1]
  • Regular clinical assessment for these symptoms is recommended, particularly in homozygous APOE ε4 patients [1]

Treatment Considerations

  • The decision to use Leqembi in a patient with homozygous APOE ε4 should carefully weigh the potential benefits against the substantially increased risk of ARIA, with particular attention to additional risk factors that might further elevate the risk of serious adverse events [1]
  • Patients requiring anticoagulation should generally not receive Leqembi until more safety data is available [1]